

Name: Theodoros Sklaviadis

Title: Professor

Current position: Professor, Aristotle University Laboratory of Pharmacology, Department of Pharmaceutical Sciences, School of Health Sciences Thessaloniki 54124, Greece

Tel 30 310 997615 fax 30 310 997720 Email sklaviad @auth.gr

Date of birth: March 24, 1956

Studies:

1980-1984 Ph.D. in Biochemistry Aristotle University of Thessaloniki

1974-1979 Diploma in Pharmaceutical Sciences Aristotle University of Thessaloniki

Appointments:

2011-now Adjunct Professor at Rockefeller University New York

2008- now Professor Aristotle University of Thessaloniki

1993-2008 Associate Professor Aristotle University of Thessaloniki

1991-1993 Assistant Professor Aristotle University of Thessaloniki

1988-1991 Assistant Professor Yale University School of Medicine Section of Neuropathology

1987-1988. Associate Research Scientist Yale University School of Medicine Section of Neuropathology

1984-1987 Postdoctoral Associate Yale University School of Medicine Section of Neuropathology

Awards:

1. NATO Collaborative Research Grant Award 1992
2. "Identification of consensus sequences that bind to human prion protein" presented by M. Sachsamanoglou, L. Varinou, V. Karagiorgis, S. Lazos and T. Sklaviadis. This poster is awarded with poster prize in category, Diagnosis (incl. Pre-and clinical diagnosis, epidemiology, characterization of the infectious agent. International Symposium on the "Characterization of Prion diseases in animals and man" Tubingen , Germany, September, 1999.
3. 1st award International Symposium Prion 2008 Madrid October 2008 for the poster "Evaluation of the possible transmission of TSEs to gilthead sea bream." presented by Evgenia Salta, Cynthia Panagiotidis, Spyros Petrakis, Eleftherios Eleftheriadis, Fotis Arapoglou, Panagiotis Aggelidis, Konstantinos Teliouis, Eleni Kaldrymidou, Grigorios Krey and Theodoros Sklaviadis Aristotle University of

Thessaloniki and Centre for Research and Technology-Hellas, Institute of Agrobiotechnology, 57001, Thessaloniki, Greece

4. 2nd award The 6th Annual Meeting of the Greek Society of Pharmacology Crete June 2010 for the oral presentation « Possible protective effect of 2,3-dihydro-2*H*-1,4-benzoxazine derivatives in scrapie-infected murine cell line» Fani Koukouli, Evgenia Salta, Theodora Calogeropoulou, Theodoros Sklaviadis

EU related activities:

1. European Commission Directorate General VI Independent expert evaluation of the third “Call for proposals” for shared cost and concerted actions. Brussels 14 to 18 February 1994
2. Meeting organizer" New Approaches in European Brain Banking Procedures and Protocols" Thessaloniki October 1994
3. European Commission Directorate General VI Independent expert evaluation of the first “Call for proposals” for shared cost, concerted actions and demonstration projects. Brussels 24 April to 12 May 1995
4. National representative. National activities for Creutzfeldt-Jakob disease. Brussels June 1996
5. Inter-Committee ad hoc group on “TSE sampling and safety procedures” Brussels June 1997
6. Delegate, expert Special joint meeting of the three programme committees Biotech-FAIR-BIOMED. Brussels September 1997
7. Joint call BIOMED/BIOTECH/FAIR on TSE related research. Opinion on draft shortlist of proposals eligible for funding. Brussels December 1997
8. European Commission Directorate General XII Independent expert evaluation of the second Joint call on TSE for shared cost, concerted actions and demonstration projects. Brussels June 29 to July 1 1998
9. Evaluation of research projects in the framework of RTD FAIR programme April 1999
10. European Commission Directorate General: Research, Programme : Quality of life and management of living resources. Key action 2 “Control of infectious diseases” Peer review evaluation January 2000.

11. European Commission Directorate General: Research, Programme : Quality of life and management of living resources. Key action 2 “Control of infectious diseases” Peer review evaluation December 2000.
12. National Delegate for “TSE research” meeting. December 2000.
13. National Delegate for “TSE research” meeting. February 2001.

Member of the German Ministry for education and research reviewer’s board for the evaluation of German TSE-Therapy research funding initiative.

Funding:

1. AIR Programme, Directorate General VI, Commission of the European Communities Characterization of the Bovine Spongiform Encephalopathy (BSE) infectious agent. PL N 920859. (coordinator) 1994-1998)
2. BIOMED-I CA, European Brain Bank Network (EBBN) for neurological studies in neurological and psychiatric disorders. PL 931359 (partner 1994-1997)
3. BIOMED-I CA, The Human Prion Diseases: From Neuropathology to Pathobiology and Molecular Genetics. PL 921484 (partner 1994-1997)
4. Greek Ministry of Health. Expression of proteins that are related with Alzheimer Creutzfeldt-Jakob disease. A2γ/1440/8-4-92 (coordinator 1992-1993)
5. BIOMED 2 Molecular biology of prion disease. The study of prion propagation, pathogenesis and intermammalian species barriers in transgenic and other models of prion disease. PL 961185 (partner 1997-2000)
6. BIOMED 2 Molecular pathology of prion disease. CJD and BSE: an integrated and experimental neuropathological analysis of prion neurodegeneration, strain variation and transmission risks PL 962679. (partner 1997-2000)
7. FAIR CA A network for the supply of BSE tissues and fluids for European collaborative research. (partner 1998-2001).
8. FAIR SC Surveillance and Diagnosis of Ruminant TSE PL 98-7021 (Partner 1998-2001).
9. BIOMED 2 SC. Prion diseases: mechanisms of transmission and identification of target for potential therapeutics PL CT 98-6040 (partner Duration: 1998-2001).

10. EPET Peptide identification with potential diagnostic and therapeutic use of neurodegenerative disorders Greek ministry of Development 97EKBAN2-1.2-35
11. QLK5-2002-00866 “Tse and Fish”: Evaluation of the possible transmission of prions (Scrapie and BSE) to different fish species. Duration: 1/12/2002-30/11/2007
12. QLK2-CT-2001-01924 “EU PRIONS”: Strategies for the prevention and treatment of prion disease. Duration: 1/11/2001-31/10/2005
13. QLG3-CT-2002-81606 “CJD MARKERS”: Early clinical diagnosis of human spongiform encephalopathies by analysis of biological fluids. Duration: 1/10/2002-30/9/2005.
14. QLK2-CT-2002-81523 Human transmissible spongiform encephalopathies: The European diagnostic laboratory. (TSELAB)
15. QLK5-2002-0059 SRTSENETWORK: European Network of Surveillance and control of TSE in Small – Ruminants (with emphasis on epidemiology, pathology and diagnostic tests).Duration: 1/2/2003-31/9/2006
16. Detection and characterization of Creutzfeldt-Jakob disease in Greece
17. MIS 88722 ΗΠΑΚΛΕΙΤΟΣ: Study of the molecular structure of the pathological agent that causes Spongiform Encephalopathies in humans and animals. Duration: 8/11/2002- 29/6/2005.
18. Generate peptides with diagnostic and therapeutic action in Transmissible Spongiform Encephalopathies Duration: 13/1/2003-13/8/2003.
19. FOOD-CT-2004-506579 NEUROPRION: Prevention, Control, Treatment, Management and Risk analysis of Prion Diseases Duration:1/9/2003-31/8/2008
20. ΕΠΙΑv.M.4.3.6.1. ε Distribution of endogenous PrP^c and evaluation of PrP^{sc} uptake in the intestines of *Sparus auratus* orally challenged with natural scrapie Duration: 8/2/2006-31/3/2008
21. 05NON-EU-186 Tissue plasminogen activator / plasminogen system as a potential target for neuroprotection for Prion Diseases Duration: 16/3/2006-15/3/2008
22. FP6-2005-FOOD-4-B -“ TSE GOAT ,“GOAT BSE” Duration: 1/12/2006-30/11/2010
23. ΕΠΙΑN II-DEMTEST Biomarker based diagnosis of rapid progressive dementias - optimisation of diagnostic protocols. Duration: 1/11/2012-31/10/2015

Selected bibliography:

1. Sklaviadis, T.K., Georgatsos, J.G. and Kyriakidis, D.A. (1985). Purification and properties of ornithine decarboxylase from *Tetrahymena pyriformis*. *Biochem. Biophys. Acta* 831:288-296.
2. Tsirka, S.A., Sklaviadis, T.K. and Kyriakidis, D.A. (1986). Non-competitive inhibition of ornithine decarboxylase by a phosphopeptide and phospho-amino acids. *Biochem. Biophys. Acta* 884:482-489. 3
3. Sklaviadis, T., Manuelidis, L. and Manuelidis E.E. (1986). Characterization of major peptides in Creutzfeldt-Jakob disease and scrapie. *Proc. Natl. Acad. Sci. USA* 83:6146-6150.
4. Manuelidis, L., Sklaviadis, T. and Manuelidis, E.E. (1987). Evidence suggesting that PrP is not the infectious agent in Creutzfeldt-Jakob disease. *EMBO J* 6:341-347.
5. Manuelidis, L., Tesin, D., Sklaviadis, T. and Manuelidis, E.E. (1987). Astrocyte gene expression in Creutzfeldt-Jakob disease. *Proc. Natl. Acad. Sci. USA* 84:5937-5941.
6. Sklaviadis, T.K., Manuelidis, L. and Manuelidis, E.E. (1989). Physical properties of the Creutzfeldt-Jakob disease agent. *J. Virol.* 63:1212-1222.
7. Murdoch, G.H., Sklaviadis, T., Manuelidis, E.E., Manuelidis, L. (1990). Potential retroviral RNAs in Creutzfeldt-Jakob disease. *J. Virol.* 64:1477-1486.
8. Sklaviadis, T., Akowitz, A., Manuelidis, E.E., Manuelidis, L. (1990). Nuclease treatment results in high specific purification of Creutzfeldt-Jakob disease infectivity with a density characteristic of nucleic acid-protein complexes. *Arch. Virol.* 112: 215-229.
9. Akowitz, A., Sklaviadis, T., Manuelidis, E.E., Manuelidis, L. (1990). Nuclease-resistant polyadenylated RNAs of significant size are detected by PCR in highly purified Creutzfeldt-Jakob disease preparations. *Microbial Pathogenesis* 9:33-45.
10. Sklaviadis, T., Dreyer, R., Manuelidis, L.(1992) Analysis of Creutzfeldt-Jakob disease infectious fractions by gel permeation chromatography and sedimentation field flow fractionation. *Virus Research* 26, 241-254.

11. Sklaviadis, T., Akowitz, A., Manuelidis, E.E., Manuelidis, L. (1993) Nucleic acid binding proteins in highly purified Creutzfeldt-Jakob disease preparations. *Proc. Natl. Acad. Sci. USA*, 90: 5713-5717.
12. Akowitz, A., Sklaviadis, T., Manuelidis, L. (1994) Endogenous viral complexes with long RNA cosediment with the agent of Creutzfeldt-Jakob Disease. *Nucl. Acids. Res.*, 22: 1101-1107.
13. Manuelidis, T. Sklaviadis, A. Akowitz, W. Fritch (1995) Viral particles are required for infection in neurodegenerative Creutzfeldt-Jakob disease *Proc. Natl. Acad. Sci. USA* , 92: 5124-5128.
14. Papaconstantinou, E., Karakioulakis, G., Roth, M., Dawson, M., Keyes, P., Papadopoulos, O., Sklaviadis, T. (1999) Glycan alterations associated with bovine spongiform encephalopathy *Archives of Biochemistry and Biophysics* 370, 250-257.
15. S. Verghese-Nikolakaki, H. Mihaloudi, M. Polymenidou, M. Groschup, G. Papadopoulos, T. Sklaviadis (1999) Expression of the prion protein in the rat forebrain-, an immunohistochemical study. *Neuroscience letters* 272, 9-12.
16. S. Leontides, V. Psychas, S. Argyroudis, A. Giannti-Stefanou, E. Paschaleri-Papadopoulou, T. Manousis, T. Sklaviadis (2000) A survey of more than 11 years of neurologic diseases of ruminants with special reference to transmissible spongiform encephalopathies (TSEs) in Greece *J. Vet. Med.* 47, 303-310
17. T. Manousis, M. Sachsamanoglou, P. Toumazos, S. Verghese-Nikolakaki, O. Papadopoulos, T. Sklaviadis (2000) Western Blot Detection of PrP (Sc) in Cyprus Sheep with Natural Scrapie. *Vet J.*, 159 (3):270-273.
18. T. Manousis, P. Keyes, I. Dexter, R. Green, M. Sachsamanoglou, M. Dawson, S. Verghese-Nikolakaki, O. Papadopoulos, T. Sklaviadis (2000) Characterization of the murine BSE infectious agent *J. Gen. Virol.* 81, 1615-1620.
19. Voigtlander T, Kloppel S, Birner P, Jarius C, Flicker H, Verghese-Nikolakaki S, Sklaviadis T, Guentchev M, Budka. Marked increase of neuronal prion protein immunoreactivity in Alzheimer's disease and human prion diseases. *Acta Neuropathol (Berl)*. 2001 May;101(5):417-23
20. C. Bilinis, C. H. Panagiotidis, V. Psyhas, S. Argyroudis, A. Nicolaou, S. Leontides, O. Papadopoulos, T. Sklaviadis (2002). Prion Protein gene polymorphisms in natural scrapie of Greek goats. *J. gen Virol* 83 , 713-721

21. M. Polymenidou, S. Vergese-Nikolakaki, M. Groschup, M.J. Chaplin, M.J. Stack, A. Plaitakis, T. Sklaviadis (2002). A short purification process for quantitative isolation of PrP^{Sc} from naturally occurring and experimental transmissible spongiform encephalopathies. *BMC Infectious Diseases* 2:23
22. Sachsamanoğlu M, Paspaltsis I, Petrakis S, Vergese-Nikolakaki S, Panagiotidis CH, Voigtlander T, Budka H, Langeveld JP, Sklaviadis T. (2004) Antigenic profile of human recombinant PrP: generation and characterization of a versatile polyclonal antiserum *J Neuroimmunol.*146:22-32
23. Billinis C, Psychas V, Leontides L, Spyrou V, Argyroudis S, Vlemmas I, Leontides S, Sklaviadis T, Papadopoulos O. (2004) Prion protein gene polymorphisms in healthy and scrapie-affected sheep in Greece *J Gen Virol.* 85:547-554. Impact Factor 3.013, 11.
24. Xanthopoulos K, Paspaltsis I, Apostolidou V, Petrakis S, Siao CJ, Kalpatsanidis A, Grigoriadis N, Tsaftaris A, Tsirka SE, Sklaviadis T. Tissue plasminogen activator in brain tissues infected with transmissible spongiform encephalopathies *Neurobiol Dis.* 2005 May 25. Impact Factor 4.048, 1
25. Rivera-Milla E, Oidtmann B, Panagiotidis CH, Baier M, Sklaviadis T, Hoffmann R, Zhou Y, Solis GP, Stuermer CA, Malaga-Trillo E. Disparate evolution of prion protein domains and the distinct origin of Doppel- and prion-related loci revealed by fish-to-mammal comparisons. *FASEB J.* 2006 Feb;20(2):317-9. Epub 2005 Dec 13.
26. Sanchez-Juan P, Green A, Ladogana A, Cuadrado-Corrales N, Saanchez-Valle R, Mitrova E, Stoeck K, Sklaviadis T, Kulczycki J, Hess K, Bodemer M, Slivarichova D, Saiz A, Calero M, Ingrosso L, Knight R, Janssens AC, van Duijn CM, Zerr I. CSF tests in the differential diagnosis of Creutzfeldt-Jakob disease. *Neurology.* 2006 Aug 22;67(4):637-43.
27. Paspaltsis I, Kotta K, Lagoudaki R, Grigoriadis N, Poullos I, Sklaviadis T. Titanium dioxide photocatalytic inactivation of prions. *J Gen Virol.* 2006 Oct;87(Pt 10):3125-30.
28. E. Triantaphyllidou, T. Sklaviadis and D.H. Vynios Detection, quantification, and glycotyping of prion protein in specifically activated enzyme-linked immunosorbent assay plates. *Anal Biochem.* 2006 Dec 15;359(2):176-82. Epub 2006
29. Spyros Petrakis, Theodoros Sklaviadis. Identification of proteins with high affinity for refolded and native PrP^C. *Proteomics.* 2006 Dec;6(24):6476-84.

30. Konstantina Kotta, Ioannis Paspaltsis, Sevasti Bostantjopoulou, Helene Latsoudis, Andreas Plaitakis, Dimitrios Kazis, John Collinge and Theodoros Sklaviadis Novel mutation of the PRNP gene of a clinical CJD case. *BMC Infect Dis.* 2006 Nov 27;6:169.
31. Green, P. Sanchez-Juan, A. Ladogana, N. Cuadrado-Corrales, R. Sa'nchez-Valle, E. Mitrova, K. Stoeck, T. Sklaviadis, J. Kulczycki, U. Heinemann, K. Hess, D. Slivarichova, A. Saiz, M. Calero, V. Mellina, R. Knight, C. M. van Duijn and I. Zerr. CSF analysis in patients with sporadic CJD and other transmissible spongiform encephalopathies 2007. *Eur.J. Neurol.* 14(2): 121-4. Impact Factor 2.244
32. Ekateriniadou LV, Panagiotidis CH, Terzis A, Ploumi K, Triantafyllidis A, Deligiannidis P, Triantaphyllidis C, Sklaviadis T. Genotyping for PrP gene polymorphisms in rare Greek breeds of sheep. *Vet Rec.* 2007 Feb 10;160(6):194-5.
33. Ekateriniadou, L.V., Kanata, E., Panagiotidis, C., Nikolaou, A., Koutsoukou, E., Lymberopoulos, A.G., Sklaviadis, T. PrP genotypes in scrapie-affected sheep in Greece-The contribution of the AHQ 1 polymorphism. 2007 *Small Ruminant Research* 73 (1-3), pp. 142-149
34. Sanchez-Juan P, Sanchez-Valle R, Green A, Ladogana A, Cuadrado-Corrales N, Mitrova E, Stoeck K, Sklaviadis T, Kulczycki J, Hess K, Krasnianski A, Equestre M, Slivarichova D, Saiz A, Calero M, Pocchiari M, Knight R, van Duijn CM, Zerr I. Influence of timing on CSF tests value for Creutzfeldt-Jakob disease diagnosis. *J Neurol.* 2007.
35. Favre-Krey L, Theodoridou M, Boukouvala E, Panagiotidis CH, Papadopoulos AI, Sklaviadis T, Krey G. Molecular characterization of a cDNA from the gilthead sea bream (*Sparus aurata*) encoding a fish prion protein. *Comp Biochem Physiol B Biochem. Mol Biol.* 2007.
36. A. Chatzitakis¹, C. Berberidou¹, I. Paspaltsis², G. Kyriakou³, T. Sklaviadis², I. Poulis^{1*} Photocatalytic degradation and drug activity reduction of Chloramphenicol. *Water Res.* 2008 Jan;42(1-2):386-94.
37. Petrakis S., Irinopoulou T., Engelstein R., Lindstrom J., Orr-Urtreger A., Gabizon R., Grigoriadis N. and Sklaviadis T. Cellular Prion protein co-localizes with nAChR β 4 subunit in brain and gastrointestinal tract. *Eur J Neurosci.* 2008 Feb;27(3):612-20.

38. S. Kunze, K. Lemke, J. Metze, G. Bloukas, K. Kotta, C. H. Panagiotidis, T. Sklaviadis^b, W. Bodemer^c. Atomic Force Microscopy to visualize the molecular size of prion protein. *J Microsc.* 2008 May;230(Pt 2):224-32
39. Canello T, Engelstein R, Moshel O, Xanthopoulos K, Juanes ME, Langeveld J, Sklaviadis T, Gasset M, Gabizon R. Methionine sulfoxides on PrPSc: a prion-specific covalent signature. *Biochemistry.* 2008 Aug 26;47(34):8866-73.
40. Ioannis Paspaltsis, Chrisanthi Berberidou, Ioannis Poullos and Theodoros Sklaviadis Photocatalytic degradation of Prions using the Photo-Fenton reagent. *J Hosp Infect.* 2009 Feb;71(2):149-56
41. Petrakis S, Malinowska A, Dadlez M, Sklaviadis T. Identification of proteins co-purifying with scrapie infectivity. *J Proteomics.* 2009 May 2;72(4):690-4.
42. Ladogana A, Sanchez-Juan P, Mitrová E, Green A, Cuadrado-Corrales N, Sánchez-Valle R, Koscova S, Aguzzi A, Sklaviadis T, Kulczycki J, Gawinecka J, Saiz A, Calero M, van Duijn CM, Pocchiari M, Knight R, Zerr I. Cerebrospinal fluid biomarkers in human genetic transmissible spongiform encephalopathies. *J Neurol.* 2009 May 15. [Epub ahead of print]
43. Xanthopoulos K, Polymenidou M, Bellworthy SJ, Benestad SL, Sklaviadis T. Species and strain glycosylation patterns of PrP. *PLoS One.* 2009 May 20;4(5):e5633.
44. Vaccari G, Panagiotidis CH, Acin C, Peletto S, Barillet F, Acutis P, Bossers A, Langeveld J, van Keulen L, Sklaviadis T, Badiola JJ, Andréoletti O, Groschup MH, Agrimi U, Foster J, Goldmann W. State-of-the-art review of goat TSE in the European Union, with special emphasis on PRNP genetics and epidemiology. *Vet Res.* 2009 May 28;40(5):48
45. Arrizubieta MJ, Kanata E, Keklikoglou I, Papasavva-Stylianou P, Toumazos P, Panagiotidis CH, Sklaviadis T. Design and validation of a high-throughput assay to detect codon 146 polymorphisms in the caprine prion protein gene. *Anal Biochem.* 2009 Jun 24.
46. E. Salta, C. Panagiotidis, Eleftheriadis, G. Krey, E Kaldremidou, S. Petrakis, , Sklaviadis, Evaluation of the Possible Transmission of BSE and Scrapie to Gilthead Sea Bream (*Sparus aurata*) *PLoS One.* 2009 Jul 28;4(7):e6175
47. Málaga-Trillo E, Salta E, Figueras A, Panagiotidis C, Sklaviadis T. Fish models in prion biology: Underwater issues. *Biochim Biophys Acta.* 2010 Oct 7.
48. Koukouli, F., Salta, E., Calogeropoulou, T., Sklaviadis, T. Possible protective effect of 2,3-dihydro-2H-1,4-benzoxazine derivatives in a prion disease model.

2010 Review of Clinical Pharmacology and Pharmacokinetics, International Edition 24 (2) , pp. 99-101

49. Jacobs, JG ; Bossers, A ; Rezaei, H ; van Keulen, LJM; McCutcheon, S; Sklaviadis, T ; Lantier, I ; Berthon, P ; Lantier, F ; van Zijderveld, FG ; Langeveld, JPM; Proteinase K-Resistant Material in ARR/VRQ Sheep Brain Affected with Classical Scrapie Is Composed Mainly of VRQ Prion Protein. J Virol. 2011 Dec;85(23):12537-46.
50. Koukouli F, Paspaltsis I, Salta E, Xanthopoulos K, Koini EN, Calogeropoulou T, Sklaviadis T. Inhibition of PrP (Sc) formation in scrapie infected N2a cells by 5,7,8-trimethyl-3,4-dihydro-2H-1,4-benzoxazine derivatives. 2012 Prion 6 (5), pp. 470-476.